Teva Launches Two Strengths of a Generic Version of Solodyn in US
26 February 2018 - - Petach Tikva, Israel-based generic and specialty medicines company Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) has launched two strengths of a generic version of Solodyn (minocycline HCl) Extended Release Tablets, 65 and 115 mg, in the US, the company said.
Minocycline Hydrochloride Extended-Release Tablets are a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
Teva is a patient-centric healthcare solutions, and generic and specialty medicines producer. It leverages its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.
In specialty medicines, the company has an innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products.